Global Launch – A New Pharma Initiative takes on the Antibiotic Innovation Challenge (Washington DC)
Date
9 July 2020
Time
3:15 PM – 5:00 PM CEST
Location
Washington, D.C. USA
Attendance
This event has now passed. To browse our upcoming events click here.
The world is losing its most powerful tool in healthcare: antibiotics. The reason is rapidly rising antibiotic-resistant infections – also called antimicrobial resistance, or AMR. The world needs new antibiotics to stem the toll superbugs are having on patients, but there are few in the pipeline. This is the result of a long-standing paradox: despite the huge societal costs of AMR, there is currently no viable market for new antibiotics. In the long term, the uncontrolled rise of AMR could have public health and economic consequences greater than COVID-19. But unlike COVID-19, AMR is a predictable and preventable crisis – we must take action now.
Launch events on 9 July from Berlin and Washington D.C and on 10 July from Tokyo.
Program
Introduction and welcome remarks
David Ricks, Chairman and CEO, Eli Lilly and Company
FIRESIDE CHAT – Patient experience with AMR
Michelle McMurry-Heath, President and CEO, BIO – moderator
Brandon Noble, former NFL player
CEO ROUNDTABLE – Collaborating to beat the public health challenge (followed by Q&A)
Steve Ubl, President and CEO, PhRMA – moderator
Albert Bourla, Chairman and CEO, Pfizer
Ken Frazier, Chairman and CEO, Merck
David Ricks, Chairman and CEO, Eli Lilly and Company
KEYNOTE REMARKS – The world urgently needs new antibiotics: Politics, leadership, and public health
ADM Brett P. Giroir, MD, Assistant Secretary for Health
Senator Bill Cassidy, MD (R-LA)
Senator Bob Casey (D-PA)
PANEL – The AMR ecosystem challenges, opportunities and policies necessary for change (followed by Q&A)
Scott Gottlieb, resident fellow, American Enterprise Institute – moderator
Helen Boucher, MD, board member and treasurer, Infectious Disease Society of America
Michael Boyle, MD, president and CEO, Cystic Fibrosis Foundation
Kevin Outterson, executive director and principal investigator, CARB-X
Kathy Talkington, director, Health Programs, The Pew Charitable Trusts
Ramani Varanasi, founder/president/CEO, X-Biotix
Closing remarks
Ken Frazier, Chairman and CEO, Merck
Speakers
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.